Har-El G, Hadar T, Segal K, Levy R, Sidi J
Cancer. 1986 Apr 15;57(8):1613-7. doi: 10.1002/1097-0142(19860415)57:8<1613::aid-cncr2820570829>3.0.co;2-3.
Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well-differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high-grade malignancies and below those of low-grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice.
许特尔细胞癌是一种罕见的甲状腺癌，在组织学上与甲状腺的高分化恶性肿瘤相关。本报告介绍了对17例（549例甲状腺癌患者中的）许特尔细胞癌患者30年的治疗经验评估。所有17例患者均接受了手术治疗。6例患者（35.3%）死于甲状腺疾病。10年和15年生存率分别为63.7%和25%。这些生存率高于甲状腺高级别恶性肿瘤的生存率，低于甲状腺低级别恶性肿瘤的生存率。包括放射性碘治疗在内的非手术治疗效果不佳；因此，建议首选初始根治性手术作为治疗方法。
